Why did Empower Pharmacy get an FDA warning letter over compounded semaglutide and tirzepatide?
Short answer · as of 2026-10-06
DOCUMENTED. FDA’s Center for Drug Evaluation and Research dated a warning letter to Empower Clinic Services, LLC, doing business as Empower Pharmacy of Houston, Texas, on Sept. 18, 2026. The letter is FDA’s allegation, not a court finding, and it is not a shutdown order.
Attribution: Compiled from FDA’s posted letter (content current as of Sept. 22, 2026) and a law-firm summary, read on October 6, 2026. Quoted phrases are FDA’s. We have not seen a company response.
What happened
FDA dated a warning letter to Empower Clinic Services, LLC, doing business as Empower Pharmacy, on Sept. 18, 2026. FDA’s page for it was current as of Sept. 22, 2026. The letter follows an inspection from Nov. 3 to 14, 2025.
On compounding rules, FDA says tirzepatide with niacinamide and semaglutide with cyanocobalamin were essentially copies of commercially available drug products, compounded regularly or in inordinate amounts. It says the prescriber statements of a “significant difference” appeared repeated verbatim across many records, suggesting they were generated in advance rather than individual clinical judgments.
On sterile production, FDA says the firm did not perform adequate smoke studies under dynamic conditions in its ISO 5 area, that media-fill validation was inadequate, and that records showed discrepancies in vial counts and unexplained “N/A” entries.
The letter cites sections 501(a)(2)(A), 501(a)(2)(B), 502(f)(1) and 505 of the Federal Food, Drug, and Cosmetic Act and prohibited acts under section 301. It gives the firm 15 working days to describe corrective actions and warns of legal action, including seizure and injunction, without further notice.
What we can verify
- The letter date, inspection period, firm name and address, cited products, response window and the seizure-and-injunction warning appear on FDA’s page as we read it.
- A law firm’s summary agrees on the letter number (738238), date and Houston location.
What remains unknown
- Whether Empower has responded, and what it told FDA.
- Whether FDA has taken any further action. We found none.
- Whether the letter addresses third-party prescribing platforms. A secondary summary says it does; we did not see it.
- What the letter means for patients with prescriptions filled there. The letter is addressed to the firm; we saw no instruction to patients.
- Whether products are still being compounded or shipped. We did not check the company’s site.
Timeline
| Date / time | Event |
|---|---|
| 2025-11-03 to 2025-11-14 | FDA inspection period cited in the letter. |
| 2026-09-18 | Date on the FDA warning letter to Empower Clinic Services, LLC. |
| 2026-09-22 | FDA’s page shows the letter content as current; a law-firm summary gives this as the posting date. |
Participating agencies
| Agency | Reported role or presence |
|---|---|
| FDA Center for Drug Evaluation and Research | Issuing office of the warning letter. |
Receipts
- FDA: Warning letter to Empower Clinic Services, LLC dba Empower Pharmacy (Sept. 18, 2026)
- Buchanan Ingersoll & Rooney: FDA warning letter to Empower Pharmacy and what it means for 503A pharmacies
Company response
No company response located as of the publish date.
Why people care
Most FDA letters in this record go to sellers of research-use-only products. This one goes to a licensed 503A pharmacy and concerns compounded GLP-1 drugs, so it speaks to how compounded copies of approved drugs are justified and how sterile production is validated. It is an allegation, and nothing here says the pharmacy’s products are unsafe.
Common questions
Why did Empower Pharmacy receive an FDA warning letter?
FDA says Empower compounded tirzepatide with niacinamide and semaglutide with cyanocobalamin that were essentially copies of commercially available drugs, that prescriber statements of a significant difference looked repeated verbatim across records, and that its sterile production had gaps in smoke studies, media fills and records. These are FDA’s allegations in a letter dated Sept. 18, 2026, not court findings.
Is Empower Pharmacy being shut down?
The letter is not a shutdown order. It gives the firm 15 working days to describe corrective actions and warns that failure to correct violations may lead to legal action, including seizure and injunction. We found no closure or further action.
Can adding a vitamin make a compounded semaglutide or tirzepatide legally different?
We state no general rule. In this letter, FDA treated tirzepatide with niacinamide and semaglutide with cyanocobalamin as essentially copies, and questioned significant-difference statements that repeated verbatim across records. FDA frames it as an individualized clinical judgment by the prescriber.
What does the letter mean for patients with prescriptions from Empower?
The letter is addressed to the company, and we saw no instruction to patients in it. Questions about a prescription belong with your prescriber or pharmacist. This is not medical advice.
Terms explained
- Does an FDA warning letter mean a company is shut down?
- How do you read an FDA warning letter?
- What does “unapproved new drug” mean?
- What does “misbranded” mean in an FDA letter?
- What is an FDA close-out letter?
Corrections and update log
No corrections or updates. Request a correction.
Related vendor records
Related stories
DOCUMENTED. FDA posted warning letters on Sept. 1, 2026 (dated Aug. 24) to five peptide sellers, stating that products sold as “research use only” are unapproved new drugs. The letters are FDA’s allegations; each firm was told to respond within 15 business days.
REPORTED. FDA’s page confirms a July 23-24, 2026 advisory committee meeting on seven peptides; outlets report the panel supported six of them (including BPC-157) for the 503A bulks list and rejected one, although FDA’s own briefing document proposed that none of the seven be included. The votes are nonbinding and a formal rule would be needed before pharmacies could compound them.
DOCUMENTED. FDA posted warning letters on Apr. 7, 2026 (dated Mar. 31) to five peptide sellers, citing unapproved new drug violations; all five letters also name bacteriostatic water sold alongside the peptides. The letters are FDA’s allegations; each firm had 15 working days to respond.